Potential roles of interleukin-17A in the development of skin fibrosis in mice

Arthritis and Rheumatism

Volumn 64, Issue 11, 2012, Pages 3726-3735

  Okamoto, Yoshinobu ^a   Hasegawa, Minoru ^a   Matsushita, Takashi ^a   Hamaguchi, Yasuhito ^a   Huu, Doanh Le ^a   Iwakura, Yoichiro ^b   Fujimoto, Manabu ^a   Takehara, Kazuhiko ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 4; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN FIBROBLAST; SKIN FIBROSIS; SKINFOLD THICKNESS; SYSTEMIC SCLEROSIS; TH1 CELL; TH17 CELL; TH2 CELL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; DISEASE MODELS, ANIMAL; FEMALE; FIBROSIS; INTERCELLULAR ADHESION MOLECULE-1; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-4; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; PROTEIN-SERINE-THREONINE KINASES; RNA, MESSENGER; SCLERODERMA, SYSTEMIC; SKIN; T-LYMPHOCYTES, HELPER-INDUCER; TH1 CELLS; TH17 CELLS; TH2 CELLS;

EID: 84868095046     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34643     Document Type: Article

References (41)

1. Varga J, Abraham D,. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557-67.
2. Gabrielli A, Avvedimento EV, Krieg T,. Scleroderma. N Engl J Med 2009; 360: 1989-2003.
3. H2 paradigm. Nat Rev Immunol 2004; 4: 583-94.
4. Boin F, De Fanis U, Bartlett SJ, Wigley FM, Rosen A, Casolaro V,. T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease. Arthritis Rheum 2008; 58: 1165-74.
5. Abraham DJ, Varga J,. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 2005; 26: 587-95.
6. Sakkas LI, Platsoucas CD,. Is systemic sclerosis an antigen-driven T cell disease? [review]. Arthritis Rheum 2004; 50: 1721-33.
7. Radstake TR, van Bon L, Broen J, Hussiani A, Hesselstrand R, Wuttge DM, et al. The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFβ and IFNγ distinguishes SSc phenotypes. PLoS One 2009; 4: e5903.
8. Korn T, Bettelli E, Oukka M, Kuchroo VK,. IL-17 and Th17 cells. Annu Rev Immunol 2009; 27: 485-517.
9. Iwakura Y, Ishigame H, Saijo S, Nakae S,. Functional specialization of interleukin-17 family members. Immunity 2011; 34: 149-62.
10. Wilson MS, Madala SK, Ramalingam TR, Gochuico BR, Rosas IO, Cheever AW, et al. Bleomycin and IL-1β-mediated pulmonary fibrosis is IL-17A dependent. J Exp Med 2010; 207: 535-52.
11. Kurasawa K, Hirose K, Sano H, Endo H, Shinkai H, Nawata Y, et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 2000; 43: 2455-63.
12. Murata M, Fujimoto M, Matsushita T, Hamaguchi Y, Hasegawa M, Takehara K, et al. Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease? J Dermatol Sci 2008; 50: 240-2.
13. Gourh P, Arnett FC, Assassi S, Tan FK, Huang M, Diekman L, et al. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther 2009; 11: R147.
14. Yamamoto T, Takagawa S, Katayama I, Yamazaki K, Hamazaki Y, Shinkai H, et al. Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999; 112: 456-62.
15. Yamamoto T, Takagawa S, Kuroda M, Nishioka K,. Effect of interferon-γ on experimental scleroderma induced by bleomycin. Arch Dermatol Res 2000; 292: 362-5.
16. Chen ES, Greenlee BM, Wills-Karp M, Moller DR,. Attenuation of lung inflammation and fibrosis in interferon-γ-deficient mice after intratracheal bleomycin. Am J Respir Cell Mol Biol 2001; 24: 545-55.
17. Ong C, Wong C, Roberts CR, Teh HS, Jirik FR,. Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma. Eur J Immunol 1998; 28: 2619-29.
18. McGaha T, Saito S, Phelps RG, Gordon R, Noben-Trauth N, Paul WE, et al. Lack of skin fibrosis in tight skin (TSK) mice with targeted mutation in the interleukin-4R α and transforming growth factor-β genes. J Invest Dermatol 2001; 116: 136-43.
19. Izbicki G, Breuer R,. IL-4 is not a key profibrotic cytokine in bleomycin-induced lung fibrosis model. J Immunol 2003; 171: 2767-8.
20. Green MC, Sweet HO, Bunker LE,. Tight-skin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton. Am J Pathol 1976; 82: 493-512.
21. Kopf M, Le Gros G, Bachmann M, Lamers MC, Bluethmann H, Kohler G,. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 1993; 362: 245-8.
22. Nakae S, Komiyama Y, Nambu A, Sudo K, Iwase M, Homma I, et al. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 2002; 17: 375-87.
23. -/- mice: role for IFNγ in activating apoptosis of hepatocytes. J Immunol 1997; 159: 1418-28.
24. Lopez-De Leon A, Rojkind M,. A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections. J Histochem Cytochem 1985; 33: 737-43.
25. Meijerink J, Mandigers C, van de Locht L, Tonnissen E, Goodsaid F, Raemaekers J,. A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. J Mol Diagn 2001; 3: 55-61.
26. Mori R, Kondo T, Nishie T, Ohshima T, Asano M,. Impairment of skin wound healing in β-1,4-galactosyltransferase-deficient mice with reduced leukocyte recruitment. Am J Pathol 2004; 164: 1303-14.
27. Akhmetshina A, Venalis P, Dees C, Busch N, Zwerina J, Schett G, et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009; 60: 219-24.
28. Gasse P, Riteau N, Vacher R, Michel ML, Fautrel A, di Padova F, et al. IL-1 and IL-23 mediate early IL-17A production in pulmonary inflammation leading to late fibrosis. PLoS One 2011; 6: e23185.
29. Mi S, Li Z, Yang HZ, Liu H, Wang JP, Ma YG, et al. Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-β1-dependent and -independent mechanisms. J Immunol 2011; 187: 3003-14.
30. Yoshizaki A, Yanaba K, Iwata Y, Komura K, Ogawa A, Akiyama Y, et al. Cell adhesion molecules regulate fibrotic process via Th1/Th2/Th17 cell balance in a bleomycin-induced scleroderma model. J Immunol 2010; 185: 2502-15.
31. Truchetet ME, Brembilla NC, Montanari E, Allanore Y, Chizzolini C,. Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease. Arthritis Res Ther 2011; 13: R166.
32. Hill GR, Olver SD, Kuns RD, Varelias A, Raffelt NC, Don AL, et al. Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma. Blood 2010; 116: 819-28.
33. Matsushita Y, Hasegawa M, Matsushita T, Fujimoto M, Horikawa M, Fujita T, et al. Intercellular adhesion molecule-1 deficiency attenuates the development of skin fibrosis in tight-skin mice. J Immunol 2007; 179: 698-707.
34. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996; 183: 2593-603.
35. Gutcher I, Donkor MK, Ma Q, Rudensky AY, Flavell RA, Li MO,. Autocrine transforming growth factor-β1 promotes in vivo Th17 cell differentiation. Immunity 2011; 34: 396-408.
36. + T cells. Immunity 2009; 30: 155-67.
37. Lee YK, Turner H, Maynard CL, Oliver JR, Chen D, Elson CO, et al. Late developmental plasticity in the T helper 17 lineage. Immunity 2009; 30: 92-107.
38. Distler JH, Distler O,. Criteria to select molecular targets for anti-fibrotic therapy. Rheumatology (Oxford) 2008; 47 Suppl 5: v12-3.
39. Genovese MC, Van den Bosch F, Roberson SA, Bojin S, Biagini IM, Ryan P, et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010; 62: 929-39.
40. Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012; 366: 1181-9.
41. Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366: 1190-9.